X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan, effective January 31, 2025. The awards consist of options to purchase 130,117 shares of X4's common stock, granted exclusively to individuals who were not previously X4 employees.
The stock options have a ten-year term and an exercise price of $0.7001 per share, matching X4's closing price on January 31, 2025. The vesting schedule spans four years, with 25% of shares vesting after 12 months and the remaining vesting monthly over the following 36 months, contingent on continued employment. These grants were approved by X4's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (XFOR) ha annunciato l'emissione di premi di incentivazione per i nuovi dipendenti nell'ambito del suo Piano di Incentivazione del 2019, con effetto dal 31 gennaio 2025. I premi consistono in opzioni per acquistare 130.117 azioni delle azioni ordinarie di X4, concesse esclusivamente a individui che in precedenza non erano dipendenti di X4.
Le opzioni azionarie hanno un termine di dieci anni e un prezzo di esercizio di $0.7001 per azione, corrispondente al prezzo di chiusura di X4 del 31 gennaio 2025. Il programma di maturazione si estende su quattro anni, con 25% delle azioni che maturano dopo 12 mesi e il resto che matura mensilmente nei successivi 36 mesi, a condizione dell'occupazione continuativa. Questi premi sono stati approvati dal Comitato per la Compensazione di X4 in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR) ha anunciado la emisión de premios de incentivo para nuevos empleados bajo su Plan de Incentivos de 2019, efectivo a partir del 31 de enero de 2025. Los premios consisten en opciones para comprar 130,117 acciones de acciones ordinarias de X4, otorgadas exclusivamente a individuos que no eran empleados de X4 anteriormente.
Las opciones de acciones tienen un plazo de diez años y un precio de ejercicio de $0.7001 por acción, que coincide con el precio de cierre de X4 del 31 de enero de 2025. El calendario de consolidación abarca cuatro años, con 25% de las acciones consolidándose después de 12 meses y el resto consolidándose mensualmente durante los siguientes 36 meses, condicionado a la continuación del empleo. Estos premios fueron aprobados por el Comité de Compensación de X4 de acuerdo con la Regla de Inclusión en Nasdaq 5635(c)(4).
X4 제약(XFOR)은 2019년 유인계획에 따라 2025년 1월 31일부터 새로운 직원에게 인센티브 수여를 발표했습니다. 이 상금은 130,117 주식의 구매 옵션으로 구성되어 있으며, 이전에 X4의 직원이 아니었던 개인에게만 부여됩니다.
주식 옵션은 10년 기간과 주당 $0.7001의 행사가격을 갖고 있으며, 이는 2025년 1월 31일 X4의 종가와 일치합니다. 주식의 귀속 일정은 4년에 걸쳐 진행되며, 25%의 주식은 12개월 후에 귀속되고 나머지는 다음 36개월 동안 매월 귀속됩니다. 이는 계속 근무하는 조건입니다. 이러한 수여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 X4의 보상 위원회에 의해 승인되었습니다.
X4 Pharmaceuticals (XFOR) a annoncé l'attribution de primes d'incitation à de nouveaux employés dans le cadre de son Plan d'Incitation 2019, prenant effet le 31 janvier 2025. Les récompenses se composent d'options d'achat de 130 117 actions de l'action ordinaire de X4, accordées exclusivement à des individus qui n'étaient pas auparavant employés par X4.
Les options d'achat d'actions ont une durée de dix ans et un prix d'exercice de 0,7001 $ par action, correspondant au prix de clôture de X4 au 31 janvier 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25% des actions qui acquièrent des droits après 12 mois, et le reste qui acquiert des droits mensuellement au cours des 36 mois suivants, sous réserve d'une poursuite d'emploi. Ces attributions ont été approuvées par le Comité de Rémunération de X4 conformément à la Règle de Cotation Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR) hat die Vergabe von Anreizprämien an neue Mitarbeiter im Rahmen seines Anreizplans von 2019 angekündigt, der am 31. Januar 2025 in Kraft tritt. Die Prämien bestehen aus Optionen zum Kauf von 130.117 Aktien der Stammaktien von X4, die ausschließlich an Personen vergeben werden, die zuvor keine Mitarbeiter von X4 waren.
Die Aktienoptionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von $0.7001 pro Aktie, was dem Schlusskurs von X4 am 31. Januar 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% der Aktien nach 12 Monaten und der Rest in den folgenden 36 Monaten monatlich fällig wird, sofern das Arbeitsverhältnis fortbesteht. Diese Vergaben wurden vom Vergütungsausschuss von X4 gemäß der Nasdaq-Listungsregel 5635(c)(4) genehmigt.
- None.
- None.
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 130,117 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication and being reviewed by the EMA for approval in the EU for the same indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts and operates a research center of excellence in Vienna, Austria. For more information, please visit www.x4pharma.com.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares are included in XFOR's January 2025 inducement awards?
What is the exercise price for XFOR's January 2025 inducement stock options?
What is the vesting schedule for XFOR's January 2025 inducement options?
How long is the term of XFOR's January 2025 inducement stock options?
